ExonHit Announces Final Terms for RedPath Acquisition | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ExonHit Therapeutics today disclosed the final terms of its proposed acquisition of RedPath.

Under the terms, which are up for a vote by shareholders, ExonHit will pay $12.5 million in cash and $10 million in stock. ExonHIt will issue 2,834,412 new shares of its stock, which represents 7.95 percent of the 35,656,294 ordinary shares that will be outstanding after the close of the purchase.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.